The 2018 U.S. Preventive Services Task Force (USPSTF) prostate cancer screening guidelines recommend that providers and patients should engage in shared decision-making about prostate-specific antigen (PSA)-based screening [5]. This evidence concerns the gene KLK3 and prostate carcinoma.